Microbot Medical Inc. announced on June 17, 2025, that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA). This patent covers the robotic manipulation of a surgical tool handle, marking a key step in the company’s global intellectual property (IP) expansion strategy.
This new patent further validates Microbot Medical's technological innovation and expands its IP portfolio, which now includes nine patents granted globally and 59 patent applications pending. This growing portfolio helps ensure the company maintains a competitive advantage for its LIBERTY System.
The company's primary objective remains focused on the U.S. market, with an anticipated Q3 2025 commercial launch of the LIBERTY system upon planned FDA clearance. However, this patent also lays the groundwork for entering international markets, particularly China, which is estimated to have approximately 2.9 million peripheral endovascular procedures annually.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.